IVIG Boya safety and effectiveness study
Part of Genetic & congenital, Immune system & allergy clinical trials.
This study tests an intravenous (IV) immunoglobulin treatment called IVIG Boya for people with certain primary immune deficiencies. It looks at how safe it is, how well it works, and how the body processes it, which may help improve immune function and reduce infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 2 and 60 years old.
- You have been diagnosed with common variable immunodeficiency (CVID) or X-linked agammaglobulinemia (XLA), which are conditions where your body doesn't make enough antibodies.
- You have not received treatment before, or you are currently on IVIG every 3 to 4 weeks at a dose between 300 and 800 mg per kg of body weight.
- If female and of childbearing age, you must have a negative pregnancy test and agree to use effective birth control during the study.
- You must be willing to switch from subcutaneous or intramuscular immunoglobulin to IVIG if your doctor thinks it's best for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an intravenous immunoglobulin (IVIG) treatment, which is a way of giving you antibodies to help fight infections. It aims to see if this treatment is safe and effective for people with certain immune deficiencies.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
This study looks at how well immunoglobulin replacement therapy works in people with low antibody levels and how it affects the immune system. It aims to help improve treatment for primary antibody immunodeficiencies.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
Hear when a new Primary Immunodeficiency Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.